This activity was originally broadcast live at the 2022 Asembia Specialty Pharmacy Summit.
This activity features a Social Worker Perspective
Program Description
Initial therapy for ovarian cancer consists of surgery and platinum-based chemotherapy, but the majority of patients with advanced-stage ovarian cancer will experience disease relapse. PARP inhibitors have demonstrated significant efficacy in the maintenance setting of patients with ovarian cancer, and their potential applications continue to expand with use in combination settings. Pharmacists must be able to differentiate indications of each approved PARP inhibitor based on disease mutation status to ensure optimal outcomes for patients. As PARP inhibitors continue to advance the treatment paradigm of ovarian cancer, pharmacists will need to stay updated on considerations and clinical data supporting their use as monotherapy and combination therapy. This activity will also examine the pharmacist’s role in mitigating and managing adverse effects associated with use of PARP inhibitors, with discussion of drug-drug interactions, necessary dose adjustments, and guideline recommendations.
Target audience: Specialty pharmacists and oncology pharmacists
Type of activity: Application
Release date: May 10, 2022
Expiration date: May 10, 2023
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Utilize the most current clinical data when recommending treatment options for patients with ovarian cancer
- Employ toxicity management strategies for PARP inhibitors used for the treatment of ovarian cancer
- Apply strategies to address barriers to patient access to PARP inhibitor therapy
Rachel Justus, PharmD, BCPS, BCOP
Clinical Pharmacist Gynecologic Oncology
Novant Health Cancer Institute
Winston-Salem, North Carolina
Megan Rees, PharmD, BCACP, CSP
Clinical Pharmacy Specialist
Residency Program Director
Trellis Rx
Summa Health Specialty Pharmacy
Akron, Ohio
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-230-H01-P. The activity is available for CE credit through May 10, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Rachel Justus, PharmD, BCPS, BCOP, and Megan Rees, PharmD, BCACP, CSP, have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff— Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Karleen Melody, PharmD; Crissy Wilson; Susan Pordon; Chloe Taccetta; and Brianna Winters have no financial relationships with commercial interests to disclose.
An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.
The information discussed here represents the views of Rachel Justus, PharmD, BCPS, BCOP, and does not necessarily reflect the views of Novant Health.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms